NasdaqGS:BGNE

Stock Analysis Report

Executive Summary

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People’s Republic of China, the United States, and internationally.

Snowflake

Fundamentals

Excellent balance sheet with high growth potential.

Share Price & News

How has BeiGene's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.3%

NasdaqGS:BGNE

0.4%

US Biotechs

1.2%

US Market


1 Year Return

-17.0%

NasdaqGS:BGNE

-10.8%

US Biotechs

1.7%

US Market

BGNE underperformed the Biotechs industry which returned -10.8% over the past year.

BGNE underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

BGNEIndustryMarket
7 Day11.3%0.4%1.2%
30 Day-6.7%0.3%4.9%
90 Day17.7%1.6%3.7%
1 Year-17.0%-17.0%-10.1%-10.8%3.9%1.7%
3 Year311.0%311.0%7.3%3.6%47.2%37.7%
5 Yearn/a2.9%-2.0%60.0%42.4%

Price Volatility Vs. Market

How volatile is BeiGene's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is BeiGene undervalued based on future cash flows and its price relative to the stock market?

33%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

BeiGene's share price is below the future cash flow value, and at a moderate discount (> 20%).

BeiGene's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

BeiGene is loss making, we can't compare its value to the US Biotechs industry average.

BeiGene is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for BeiGene, we can't assess if its growth is good value.


Price Based on Value of Assets

BeiGene is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is BeiGene expected to perform in the next 1 to 3 years based on estimates from 18 analysts?

53.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

BeiGene's revenue is expected to grow significantly at over 20% yearly.

BeiGene's earnings are expected to grow significantly at over 20% yearly.

BeiGene's revenue growth is expected to exceed the United States of America market average.

BeiGene's earnings growth is expected to exceed the United States of America market average.

BeiGene's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if BeiGene will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has BeiGene performed over the past 5 years?

-67.1%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

BeiGene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare BeiGene's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare BeiGene's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if BeiGene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if BeiGene has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if BeiGene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is BeiGene's financial position?


Financial Position Analysis

BeiGene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

BeiGene's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

BeiGene's level of debt (15.8%) compared to net worth is satisfactory (less than 40%).

BeiGene had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 7.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

BeiGene has sufficient cash runway for 2.1 years based on current free cash flow.

Unable to confirm if BeiGene has at least 1 year of cash runway based on growing free cash flows without relevant data.


Next Steps

Dividend

What is BeiGene's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate BeiGene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate BeiGene's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as BeiGene has not reported any payouts.

Unable to verify if BeiGene's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as BeiGene has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of BeiGene's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of BeiGene's salary, the management and board of directors tenure and is there insider trading?

4.2yrs

Average management tenure


CEO

John Oyler (51yo)

9.7yrs

Tenure

US$27,895,819

Compensation

Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009.  ...


CEO Compensation Analysis

John's remuneration is higher than average for companies of similar size in United States of America.

John's compensation has increased whilst company is loss making.


Management Age and Tenure

4.2yrs

Average Tenure

56yo

Average Age

The tenure for the BeiGene management team is about average.


Board Age and Tenure

5.8yrs

Average Tenure

58yo

Average Age

The tenure for the BeiGene board of directors is about average.


Insider Trading

BeiGene individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$102,75527 Aug 19
Yung-cheng Chen
EntityIndividual
Shares714
Max PriceUS$143.91
SellUS$741,54602 May 19
Xiaobin Wu
EntityIndividual
Role
President
GM of China & President
Shares5,955
Max PriceUS$125.55
SellUS$2,037,82518 Mar 19
Donald Glazer
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares14,973
Max PriceUS$136.10

Ownership Breakdown


Management Team

  • John Oyler (51yo)

    Co-Founder

    • Tenure: 9.7yrs
    • Compensation: US$27.90m
  • Howard Liang (56yo)

    CFO & Chief Strategy Officer

    • Tenure: 4.2yrs
    • Compensation: US$3.94m
  • Scott Samuels

    Senior VP & General Counsel

    • Tenure: 0yrs
  • Luo Lusong

    Head of Discovery Biology & Senior VP

    • Tenure: 8.9yrs
  • Wei Min

    Head of Molecular Sciences and Senior Vice President

    • Tenure: 3yrs
  • Xiaodong Wang (56yo)

    Co-Founder

    • Tenure: 8.7yrs
    • Compensation: US$6.06m
  • Steve Young

    Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Jane Huang (46yo)

    Chief Medical Officer of Hematology

    • Tenure: 3yrs
    • Compensation: US$3.46m
  • Lucy Li

    Investor Contact

    • Tenure: 0yrs
  • Xiaobin Wu (57yo)

    GM of China & President

    • Tenure: 1.3yrs

Board Members

  • John Oyler (51yo)

    Co-Founder

    • Tenure: 9.7yrs
    • Compensation: US$27.90m
  • Thomas Malley (50yo)

    Independent Non-Executive Director

    • Tenure: 3.7yrs
    • Compensation: US$368.54k
  • Donald Glazer (75yo)

    Independent Non-Executive Director

    • Tenure: 6.6yrs
    • Compensation: US$358.54k
  • Ron Levy

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Neal Rosen (69yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Charles Sawyers (60yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • David Schenkein (62yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Xiaodong Wang (56yo)

    Co-Founder

    • Tenure: 8.7yrs
    • Compensation: US$6.06m
  • Steve Young

    Acting Head of Medicinal Chemistry & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michael Yi (47yo)

    Independent Non-Executive Director

    • Tenure: 4.9yrs
    • Compensation: US$373.54k

Company Information

BeiGene, Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: BeiGene, Ltd.
  • Ticker: BGNE
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$8.128b
  • Shares outstanding: 60.57m
  • Website: https://www.beigene.com

Number of Employees


Location

  • BeiGene, Ltd.
  • No.30 Science Park Road
  • Zhong-Guan-Cun Life Science Park
  • Beijing
  • 102206
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BGNENasdaqGS (Nasdaq Global Select)YesSPONSORED ADRUSUSDFeb 2016
49BADB (Deutsche Boerse AG)YesSPONSORED ADRDEEURFeb 2016
BGNE NBMV (Bolsa Mexicana de Valores)YesSPONSORED ADRMXMXNFeb 2016
49BDB (Deutsche Boerse AG)USD0.0001DEEURAug 2018
6160SEHK (The Stock Exchange of Hong Kong Ltd.)USD0.0001HKHKDAug 2018

Biography

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People’s Republic of China, the United ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:36
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.